ReviewNuclear medicine and molecular imaging2025
Advances and Challenges in the Application of Radiolabeled Magnetic Nanoparticles for Cancer Theranostics.
Review in Nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bridging the Gap in Theranostics: Where Do We Stand?Nuclear medicine and molecular imaging · 2025Article
- Challenges and Future Prospects of Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in Nanomedicine: A Focus on Toxicity, Imaging, and Theranostics.Avicenna journal of medical biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiolabeled magnetic nanoparticles (MNPs), particularly superparamagnetic iron oxide nanoparticles (SPIONs), have gained significant attention in the field of cancer theranostics due to their potential in targeted therapy and molecular imaging. This review highlights recent advancements in the development of various radiolabeled SPIONs, including those functionalized with polyethylene glycol (PEG), DTPA, and other targeting agents. These nanoparticles are designed for multiple clinical applications, including hyperthermia, magnetic resonance imaging (MRI), and radiotherapy. However, the translation of these promising nanostructures into clinical practice faces several challenges, such as issues with surface functionalization, toxicity, stability, and the complexities of multimodal imaging. The review also explores creative approaches to overcome these challenges, such as designing multicomponent nanostructures, utilizing chelator-based and chelator-free radiolabeling techniques, employing click chemistry for radiolabeling, and enhancing biocompatibility methods. Ultimately, radiolabeled SPIONs have the potential to revolutionize cancer treatment and imaging, but further optimization is required to overcome existing obstacles and enhance their clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.